Norway's Medistim Q4 sales rise 20.6% driven by strong growth in Americas, EMEA

Medistim ASA

27/02/2026 07:42

Overview

Norwegian medical device firm reported Q4 sales up 20.6% to NOK 182.3 mln

Q4 operating profit (EBIT) grew 64% to NOK 42.3 mln, achieving a 23.2% margin

Company proposes NOK 8.00 per share dividend, totaling NOK 146.2 mln

Outlook

Medistim did not provide specific guidance for future quarters or the upcoming year

Result Drivers

REGIONAL SALES - Strong currency neutral growth in Americas and EMEA, up 44.3% and 24.4% respectively, while APAC declined 24.2%

PRODUCT SALES - Currency neutral sales of own products increased 25.6% for the quarter

CASH POSITION - Solid cash position at quarter end with MNOK 212.1, no interest-bearing bank loans

Company press release: ID:nObifG3F6a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EBIT
NOK 42.30 mln


Analyst Coverage

The one available analyst rating on the shares is "strong buy"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Medistim ASA is NOK255.00, about 19.2% above its February 26 closing price of NOK214.00

The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 36 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)